



## Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results

August 2, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2022 financial results after the U.S. financial markets close on Tuesday, August 9, 2022. Oncternal's management will host a webcast at 2:00 p.m. PT ( 5:00 p.m. ET) to provide a comprehensive business update and discuss the Company's financial results.

The live webcast of the call will be available online at [investor.oncternal.com](http://investor.oncternal.com) and the call will be archived there for at least 30 days.

### About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. The clinical pipeline includes [zilovetamab](#) an investigational monoclonal antibody designed to inhibit ROR1, a type I tyrosine kinase-like orphan receptor. Zilovetamab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), in investigator-initiated studies, including a Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer, in a Phase 2 clinical trial of zilovetamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, and in a Phase 1b study of zilovetamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Oncternal is also developing [ONCT-808](#), a chimeric antigen receptor T cell (CAR-T) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. The early-stage pipeline also includes [ONCT-534](#), a dual-action androgen receptor inhibitor (DAARI), that is in preclinical development as a potential treatment for castration resistant prostate cancers, including those with clinically important resistance to approved androgen receptor inhibitors. More information is available at <https://oncternal.com/>.

### Contact Information:

#### Investors

Richard Vincent  
858-434-1113  
[rvincent@oncternal.com](mailto:rvincent@oncternal.com)

#### Media

Corey Davis, Ph.D.  
LifeSci Advisors  
212-915-2577  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)



Source: Oncternal Therapeutics